◐ Shell
reader mode source ↗
Jump to content
From Wikipedia, the free encyclopedia

Pharmaceutical compound
4-AcO-MALT
Clinical data
Other names4-Acetoxy-MALT; 4-Acetoxy-N-methyl-N-allyltryptamine
Routes of
administration		Oral
Drug classSerotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • [3-[2-[methyl(prop-2-enyl)amino]ethyl]-1H-indol-4-yl] acetate
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC16H20N2O2
Molar mass272.348 g·mol−1
3D model (JSmol)
  • C=CCN(CCc1c[nH]c2c1c(ccc2)OC(=O)C)C
  • InChI=1S/C16H20N2O2/c1-4-9-18(3)10-8-13-11-17-14-6-5-7-15(16(13)14)20-12(2)19/h4-7,11,17H,1,8-10H2,2-3H3
  • Key:PGBFYUDKPCYIEB-UHFFFAOYSA-N

4-AcO-MALT, also known as 4-acetoxy-N-methyl-N-allyltryptamine, is a psychedelic drug of the tryptamine family.[1][2][3] It is the acetate ester of 4-HO-MALT.[1][2][3]

Use and effects

[edit]

Interactions

[edit]

Pharmacology

[edit]

Pharmacodynamics

[edit]

4-AcO-MALT is assumed to act as a prodrug of the serotonergic psychedelic 4-HO-MALT.[1] 4-HO-MALT is a serotonin receptor modulator, including acting as an agonist of the serotonin 5-HT2 receptors.[2] The receptor interactions of 4-AcO-MALT have also been studied.[2][3]

Chemistry

[edit]

Analogues

[edit]

Analogues of 4-AcO-MALT include methylallyltryptamine (MALT), 4-HO-MALT (maltocin), 5-MeO-MALT, 4-AcO-DMT (psilacetin), 4-AcO-MET (metacetin), 4-AcO-MPT, 4-AcO-MiPT (mipracetin), and 4-AcO-DALT, among others.

History

[edit]

4-AcO-MALT was first described in the scientific literature by at least 2021.[1] It has been encountered as a novel designer drug.[4][5]

See also

[edit]

References

[edit]
  1. 1 2 3 4
  2. 1 2 3 4 Glatfelter GC, Naeem M, Pham DN, Golen JA, Chadeayne AR, Manke DR, et al. (April 2023). "Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice". ACS Pharmacology & Translational Science. 6 (4): 567–577. doi:10.1021/acsptsci.2c00222. PMC 10111620. PMID 37082754.
  3. 1 2 3 Jain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, et al. (July 2025). "The polypharmacology of psychedelics reveals multiple targets for potential therapeutics" (PDF). Neuron. doi:10.1016/j.neuron.2025.06.012. PMID 40683247.
  4. ↑ Miller JJ, Yazdanpanah M, Colantonio DA, Beriault DR, Delaney SR (2024). "New Psychoactive Substances: A Canadian perspective on emerging trends and challenges for the clinical laboratory". Clinical Biochemistry. 133–134 110810. doi:10.1016/j.clinbiochem.2024.110810. PMID 39181179.
  5. ↑ Axelsson MA, Lövgren H, Kronstrand R, Green H, Bergström MA (2022). "Retrospective identification of new psychoactive substances in patient samples submitted for clinical drug analysis". Basic & Clinical Pharmacology & Toxicology. 131 (5): 420–434. doi:10.1111/bcpt.13786. ISSN 1742-7835. PMID 36028947.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=4-AcO-MALT&oldid=1338630003"